Pharmalot… Pharmalittle… Good Morning
1 CommentBy Ed Silverman // March 3rd, 2011 // 7:00 am
Rise and shine, everyone, another shiny day is on the way. What lies in store? Meetings and deadlines, no doubt, and we relate. To cope, we are brewing our mandatory cup of stimulation and invite you to join us. Meanwhile, we will pause to hustle one of the short people off to the local schoolhouse. So here are a few tidbits. Also, please note that we posted some items last night, but placed them above our morning greeting in the event some people did not see them. Have a great day and stay in touch…
Traditional Drug Discovery Model Is Ripe For Reform (Nature)
McKesson Fights $212M Pricing Fine Levied By Arizona (Courthouse News)
Lilly To Outsource Bioanalytical Work (Pharma Times)
Eisai To Cut 900 Jobs Over Five Years (Bloomberg News)
Panel Told No Guarantees Against Unethical Research (New York Times)
WHO: SFDA Approval To Boost Global Vaccine Supply (InPharma Technologist)
Proton Pump Inhibitors Can Lower Magnesium Levels (Reuters)
Bayer Boasts Xarelto Will Squash Pradaxa (Pharma Times)
Glaxo CEO Compensation Was Cut Due To Missed Targets (Dow Jones)
Sanofi Plans Autonomy For Part Of Genzyme (Associated Press)
Women Are Underrepresented In Heart Device Studies (Bloomberg News)
industry insider
Nice to see that Lilly has caught to where the industry was 20 ago.